Shares of Alkermes (ALKS) were up 30 percent in 2015 and the biotech company’s strong pipeline for psychiatric drugs bodes well for another strong year in the market, said Michael Kramer, CEO of Mott Capital. 'Their lead drug for a major depressive disorder should have phase three results coming in the first quarter of this year,' said Kramer. 'Previous studies had indicated that patients who had major depressive disorders showed results within in seven days which is very impressive.' Kramer is also constructive on Tesla (TSLA), which saw its stock rise around 13 percent in 2015. The electric automaker’s shares sank almost 7 percent on Monday after the company said it delivered 50,580 vehicles in 2015, including 17,400 in the fourth quarter. The total surpassed Tesla’s guidance of 50,000 cars, yet Wall Street analysts were hoping for a number closer to 55,000. TheStreet's Gregg Greenberg has details from New York.
More from Emerging Markets
Asia's Worst-Performing Stock Market Suddenly Becomes Its Best
The stock market in the Philippines has surged by one-fifth in just over a month amid reasons for optimism.
There's Another Stock Market Rally That Makes Little Sense
Mom and pop investors have gone wild in Malaysia, driving volume to record highs and shares of rubber-glove makers through the roof.
9 Bargain Stocks to Watch in Asia's Worst-Performing Market
Indonesian stocks have done poorly this year, but these nine stocks could rate attention if investors rediscover the market.
Next Up: How Do You Contain the Dollar Virus?
A U.S. dollar that is rising in value against most other currencies is creating a huge problem for a world inundated with dollar-priced debt.
First, Bank of Japan, the U.S. and Russia: Who's Next on the Money Train?
As global markets breached their key 200-day moving averages and with uptrends being tested, there were rumours of globally coordinated central bank easing.